La Lettre de l’Hépato-gastroentérologue • Vol. XIII - n° 2 - mars-avril 2010 | 55
DOSSIER THÉMATIQUE
et de son RTK c-Met a été rapportée dans de
nombreux cancers dont le cancer gastrique
(28, 29). Un inhibiteur multicible c-Met/VEGFR2
(GSK089) et un anticorps monoclonal humain
(AMG102) sont en cours d’évaluation (30, 31)
[cf. infra]. ■
1. Wagner AD, Grothe W, Haerting J et al. Chemothe-
rapy in advanced gastric cancer: a systematic review
and meta-analysis based on aggregate data. J Clin Oncol
2006;24:2903-9.
2. Bang Y, Chung H, Xu J, Lordick F et al. Pathological
features of advanced gastric cancer (GC): Relationship to
human epidermal growth factor receptor 2 (HER2) positi-
vity in the global screening programme of the ToGA trial
(abstract). J Clin Oncol 2009;27(suppl15S):4556a
3. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick
F, et al. Efficacy results from the ToGA trial: A phase III study
of trastuzumab added to standard chemotherapy (CT) in
first-line human epidermal growth factor receptor 2 (HER2)-
positive advanced gastric cancer (GC) (abstract). J Clin
Oncol 2009;27(suppl 18s):LBA4509
4. Kim JW, Kim HP, Im SA et al. The growth inhibitory effect of
lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase,
in gastric cancer cell lines. Cancer Lett 2008;272:296-306.
5. Hecht JR, Urba SG, Koehler M et al. Lapatinib mono-
therapy in recurrent gastrointestinal malignancy: phase II
efficacy and biomarker analyses (abstract). In: Proc ASCO,
Gastrointestinal Cancers Symposium; 2008;43a
6. Kim TY, Bang YJ, Kim WS et al. Mutation of ras oncogene
in gastric adenocarcinoma: association with histological
phenotype. Anticancer Res 1997;17(2B):1335-9.
7. Lee KH, Lee JS, Suh C et al. Clinicopathologic significance
of the K-ras gene codon 12 point mutation in stomach
cancer. An analysis of 140 cases. Cancer 1995;75:2794-801.
8. Lee SH, Lee JW, Soung YH et al. BRAF and KRAS mutations
in stomach cancer. Oncogene 2003;22:6942-5.
9. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J,
Benedetti JK, Baker AF, et al. Phase II trial of erlotinib in
gastroesophageal junction and gastric adenocarcinomas:
SWOG 0127. J Clin Oncol 2006;24:4922-7.
10. Rojo F, Tabernero J, Albanell J et al. Pharmacody-
namic studies of gefitinib in tumor biopsy specimens from
patients with advanced gastric carcinoma. J Clin Oncol
2006;24:4309-16.
11. Pinto C, Di Fabio F, Siena S et al. Phase II study of
cetuximab in combination with FOLFIRI in patients with
untreated advanced gastric or gastroesophageal junc-
tion adenocarcinoma (FOLCETUX study). Ann Oncol
2007;18:510-7.
12. Lordick F, Lorenzen S, Hegewisch-Becker S et al.
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in
first-line metastatic gastric cancer: a phase II study of the
Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J
Cancer 2010;102:500-5.
13. Kanzler S, Trarbach T, Seufferlein T et al. Cetuximab
with irinotecan/folinic acid/5-FU as first-line treat-
ment in advanced gastric cancer: A nonrandomized
multicenter AIO phase II study (abstract). J Clin Oncol
2009;27(suppl15s):4534a
14. Han SW, Oh DY, Im SA et al. Phase II study and biomarker
analysis of cetuximab combined with modified FOLFOX6 in
advanced gastric cancer. Br J Cancer. 2009;100:298-304.
15. Pinto C, Di Fabio F, Barone C et al. Phase II study of
cetuximab in combination with cisplatin and docetaxel in
patients with untreated advanced gastric or gastro-oeso-
phageal junction adenocarcinoma (DOCETUX study). Br J
Cancer 2009;101:1261-8.
16. Zhang X, Xu J, Shen L et al. A phase II study of cetuximab
with cisplatin and capecitabine as 1st line treatment
in advanced gastric cancer (abstract). In: Proc ASCO,
Gastrointestinal Cancers Symposium 2009; LBA39
17. Woell E, Greil R, Eisterer W et al. Oxaliplatin, irinotecan,
and cetuximab in advanced gastric cancer. First efficacy
results of a multicenter phase II trial (AGMT Gastric-2) of
the Arbeitsgemeinschaft Medikamentoese Tumortherapie
(AGMT) (abstract). J Clin Oncol 2009;27(Suppl.15s):4538a.
18. Yeh K, Hsu C, Hsu C et al. Phase II study of cetuximab
plus weekly cisplatin and 24-hour infusion of high-dose
5-fluorouracil and leucovorin for the first-line treat-
ment of advanced gastric cancer (abstract). J Clin Oncol
2009;27(Suppl.15s):4567a.
19. Ma HY, Newman E, Ryan T et al. Neoadjuvant therapy of
gastric cancer with cetuximab added to both irinotecan and
cisplatin, followed by surgical resection and adjuvant chemo-
radiation (abstract). J Clin Oncol 2009;27(suppl15s):15552e
20. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter
phase II study of irinotecan, cisplatin, and bevacizumab
in patients with metastatic gastric or gastroesophageal
junction adenocarcinoma. J Clin Oncol 2006;24:5201-6.
21. Enzinger PC, Ryan DP, Regan EM et al. Phase II trial
of docetaxel, cisplatin, irinotecan, and bevacizumab in
metastatic esophagogastric cancer (abstract). J Clin Oncol
2008;26(May 20suppl):4552a
22. El-Rayes BF, Patel B, Zalupski M et al. A phase II study of
bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ
cancer (abstract). J Clin Oncol 2009;27(Suppl.15s):4563a.
23. Kelsen D, Jhawer M, Ilson D et al. Analysis of survival
with modified docetaxel, cisplatin, fluorouracil (mDCF), and
bevacizumab (BEV) in patients with metastatic gastroeso-
phageal (GE) adenocarcinoma: Results of a phase II clinical
trial(abstract) . J Clin Oncol 2009;27(suppl15s):4512a
24. Gilliam AD, Watson SA, Henwood M et al. A phase
II study of G17DT in gastric carcinoma. Eur J Surg Oncol
2004;30:536-43.
25. Li QL, Ito K, Sakakura C et al. Causal relationship
between the loss of RUNX3 expression and gastric cancer.
Cell 2002;109:113-24.
26. Bramhall SR, Hallissey MT, Whiting J et al. Marimastat
as maintenance therapy for patients with advanced gastric
cancer : a randomized trial. Br J Cancer 2002;86:1864-70.
27. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K,
et al. Phase I clinical and pharmacokinetic study of RAD001
(everolimus) administered daily to japanese patients with
advanced solid tumors. Jpn J Clin Oncol 2010;40(1):17-23.
28. Maulik G, Shrikhande A, Kijima T et al. Role of the hepa-
tocyte growth factor receptor, c-Met, in oncogenesis and
potential for therapeutic inhibition. Cytokine Growth Factor
Rev 2002;13:41-59.
29. Lee KH, Choi EY, Hyun MS et al. Hepatocyte growth
factor/c-met signaling in regulating urokinase plasminogen
activator in human stomach cancer: A potential therapeutic
target for human stomach cancer. Korean J Intern Med
2006;21:20-7.
30. Jhawer M, Kindler HK, Wainberg Z et al. Assessment of
two dosing schedules of GSK1363089 (GSK089), a dual
MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC):
Interim results of a multicenter phase II study (abstract). J
Clin Oncol 2009;27(Suppl.15s):4502a.
31. Burgess T, Coxon A, Meyer S et al. Fully human mono-
clonal antibodies to hepatocyte growth factor with
therapeutic potential against hepatocyte growth factor/c-
Met-dependent human tumors. Cancer Res 2006;66:1721-9.
Références bibliographiques